MDMA (3,4-Methylenedioxymethamphetamine) was first synthesised in 1912 by chemists at the pharmaceutical company, Merck in Germany. In 1985, MDMA was placed in schedule 1, resulting in no research being conducted into the potential therapeutic applications of MDMA between 1985 – 2000. However, since then, MDMA has been included in over 5000 academic articles and administered to over 1100 human volunteers.
MDMA is currently experiencing a scientific resurgence. The Multidisciplinary Association for Psychedelic Studies (MAPS) has sponsored 12 completed clinical trials globally, investigating MDMA-assisted psychotherapy for PTSD, anxiety related to advanced-stage illness, social anxiety in autistic adults, and an ongoing study of healthy subjects via the MDMA therapist training program, with plans for additional studies of MDMA therapy for race-based trauma and transgendered people as well.
As future doctors, it is important that medical students are aware of the benefits and potential harms of MDMA. These slide sets will enable future doctors to provide patients with valuable information and help support them in their decisions about their treatment plan. Medical students will also be in a position to help make real change to policy by helping to gather patient data and help provide unbiased information about the benefits and potential harms of MDMA.
About these modules
These slides were made in collaboration with Mind Medicine Australia, who are seeking to establish safe and effective psychedelic-assisted treatments for mental illness in Australia.
These slides are primarily for use in medical education settings but have been carefully designed to ensure that they are accessible for a wide range of people. They will therefore provide a rapid overview for medical students and other healthcare professionals. They are free to use; the aim of both organisations is to optimise dissemination of research into practice, so if these slides are of use to you, please use them.